Disclosure, Recusal and Management Plans

Part of Conflict of Interest in Clinical Research: Managing and Documenting Conflicts.

About 5 minutes. Free, in your language, no account needed.

Expert review pending. CRLN wrote this lesson against the primary sources listed under References. A subject-matter expert has not yet reviewed it. Where your institution's policy or your sponsor's instructions are stricter, follow them.

Why this matters

Recognizing a conflict is the start. What protects participants and data is what happens next: a clear disclosure, a decision by someone independent, and a written plan that people actually follow. This lesson walks through those three steps and the tools a plan can use.

Step 1: Disclose fully and in writing

A good disclosure is specific. It says:

• what the interest is (shares, consulting agreement, patent, relationship);
• with whom (the company, its parent, or its CRO);
• how much, where money is involved, and over what period;
• whose it is (yours, your spouse's, your dependent child's);
• which studies and tasks it could touch.

Put it on the form your institution or sponsor uses, and keep a copy. A hallway mention to the investigator is a good first step, but it is not a disclosure on record.

If you are unsure whether something is disclosable, disclose it and say you are unsure. Reviewers can set aside an interest that does not matter; they cannot manage one they never hear about.

Step 2: Someone independent decides

The person with the interest does not decide whether it is a conflict. In US federally funded research, the institution's designated official decides whether an interest is related to the research and whether it is a financial conflict of interest, and the institution may involve the investigator in that determination (42 CFR 50.604(f)). Where there is no conflict office, the decision may sit with the investigator (for staff), the sponsor, the IRB, or a site leader without a stake. Know who it is at your site.

Step 3: A written management plan

When a conflict is found, the response is a plan. In US federally funded research, the plan must specify the actions taken and to be taken to manage the conflict, and the institution monitors compliance with it until the project ends (42 CFR 50.605(a)(1) and (4)). The rule's examples of conditions are a useful menu for any site:

1. Public disclosure, for example when presenting or publishing.
2. Disclosure to participants, for human subjects research.
3. An independent monitor able to protect the design, conduct and reporting against bias.
4. Modifying the research plan.
5. Changing personnel or their responsibilities, or disqualifying a person from all or part of the research.
6. Reducing or eliminating the interest, for example selling equity.
7. Severing the relationship that creates the conflict.

(42 CFR 50.605(a)(1)(i) to (vii).)

FDA's rule points the same way. Form FDA 3455 asks for any steps taken to minimize the potential for bias (21 CFR 54.4(a)(3)(v)), and FDA notes that multiple investigators, blinding, objective endpoints and measurement of endpoints by someone other than the investigator may protect against bias (21 CFR 54.5(b)).

Recusal

Recusal means stepping out of a specific decision or task because of an interest. It is the most common management tool at site level:

• an investigator with equity does not rate the primary endpoint;
• a coordinator does not consent her own relative;
• an IRB member with a conflicting interest leaves the review except to provide information requested (21 CFR 56.107(e); 45 CFR 46.107(d)), and under ICH E6(R3) only members independent of the investigator and sponsor vote (Annex 1 §1.3.1).

For recusal to work, it must be specific (which tasks), documented (in the plan and, for delegated trial tasks, in the delegation records), and real: the person who steps out must not steer the decision informally. Because the investigator keeps ultimate responsibility for delegated work (ICH E6(R3) Annex 1 §2.3.1), the investigator should know about every recusal on the study.

Timing

Plans must be in place before the conflict can affect the work. In US federally funded research, the institution reviews disclosures and implements any plan before spending award funds, and within 60 days for a new disclosure during the award, with interim measures possible in the meantime (42 CFR 50.605(a)(1) and (2)). At any site, a reasonable rule is: no affected task until the decision is made.

Following the plan

A plan that sits in a file protects no one. Practical habits:

• read your plan and keep a copy in your own records;
• tell colleagues who need to know which tasks you do not perform;
• raise it when the study changes, such as a new amendment, a new role or a new interest;
• report a lapse, including your own, as soon as you notice it.

In US federally funded research, failure to follow a management plan is noncompliance that triggers a retrospective review within 120 days (42 CFR 50.605(a)(3)).

In practice

A sub-investigator discloses a new speaker agreement with the sponsor. The conflict office decides the interest is a conflict for the trial she works on and issues a plan: she may continue safety assessments, may not perform primary efficacy ratings, and must disclose the agreement in any presentation of the results. The investigator updates the delegation records, tells the coordinator, and files the plan in the investigator site file as the institution directs.

Key takeaways

• Disclose in writing and in detail: what, with whom, how much, whose, and which tasks it touches.
• Someone independent decides whether an interest is a conflict and how to manage it.
• Management plans draw from a standard menu: disclosure, independent monitoring, changing roles, reducing the interest, or ending the relationship.
• Recusal must be specific, documented and real.
• Follow the plan, and report lapses promptly.

References

• 42 CFR 50.604(f); 50.605(a)(1) to (4), eCFR.
• 21 CFR 54.4(a)(3)(v) and 54.5(b), eCFR.
• 21 CFR 56.107(e); 45 CFR 46.107(d), eCFR.
• ICH E6(R3), Step 4, 6 January 2025: Annex 1 §1.3.1, §2.3.1.